Lyell Immunopharma, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Lyell Immunopharma, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $522.00K, a 185.25% increase year-over-year.
- Lyell Immunopharma, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $182.00K, a 58.45% decline year-over-year.
- Lyell Immunopharma, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- Lyell Immunopharma, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $183.00K, a 77.41% decline year-over-year.
- Lyell Immunopharma, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $365.00K, a 70.75% decline from fiscal 2024.
- Lyell Immunopharma, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.25M, a 34.11% decline from fiscal 2023.
- Lyell Immunopharma, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $1.89M, a 24.69% increase from fiscal 2022.
- Lyell Immunopharma, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $1.52M.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $522.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $365.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2025-06-30 | $183.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $438.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.25M 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2024-06-30 | $810.00K 10-Q · filed 2025-08-12 | |
| 2023-12-31 | $731.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.89M 10-K · filed 2026-03-12 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $1.16M 10-Q · filed 2024-08-07 | |
| 2022-12-31 | $632.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.52M 10-K · filed 2025-03-11 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | |
| 2022-06-30 | $887.00K 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |